TY - JOUR
T1 - The treatment goals of people recently diagnosed with schizophrenia using best–worst scaling
AU - Bridges, John F.P.
AU - Beusterien, Kathleen
AU - Heres, Stephan
AU - Such, Pedro
AU - Sánchez-Covisa, Joaquín
AU - Nylander, Anna Greta
AU - Chan, Elcie
AU - de Jong-Laird, Anne
N1 - Funding Information:
The authors gratefully acknowledge the participating clinical centers: Ospedale San Gerardo di Monza (Italy) with Principal Investigator (PI) Prof Massimo Clerici, Azienda Ospedaliera “Sant’Andrea”di Roma (Italy) with PI Prof Paolo Girardi, Vivantes Klinikum am Urban – Berlin (Germany) with PI Dr Karolina Leopold, Cambridgeshire and Peterborough Foundation Trust (UK) with PI Prof Jesús Pérez and Leicestershire Partnership NHS Trust (UK) with PI Dr Debasis Das. We also thank Kaitlan Amos, BS, for her assistance in survey programming and statistical analysis. An abstract of this paper was presented at the 2017 30th European College of Neurop-sychopharmacology (ECNP) Congress, 2–5 September 2017, as a poster presentation. This work was supported by Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S.
Funding Information:
The authors gratefully acknowledge the participating clinical centers: Ospedale San Gerardo di Monza (Italy) with Principal Investigator (PI) Prof Massimo Clerici, Azienda Ospedaliera “Sant’Andrea”di Roma (Italy) with PI Prof Paolo Girardi, Vivantes Klinikum am Urban – Berlin (Germany) with PI Dr Karolina Leopold, Cambridgeshire and Peterborough Foundation Trust (UK) with PI Prof Jesús Pérez and Leicestershire Partnership NHS Trust (UK) with PI Dr Debasis Das. We also thank Kaitlan Amos, BS, for her assistance in survey programming and statistical analysis. An abstract of this paper was presented at the 2017 30th European College of Neuropsychopharmacology (ECNP) Congress, 2–5 September 2017, as a poster presentation. This work was supported by Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S.
Publisher Copyright:
© 2018 Bridges et al.
PY - 2018
Y1 - 2018
N2 - Objective: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. Methods: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. Results: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). Conclusions: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.
AB - Objective: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. Methods: People aged 18–35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best–worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. Results: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight =19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). Conclusions: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.
KW - Preferences
KW - Recent-onset schizophrenia
KW - Treatment goals
UR - http://www.scopus.com/inward/record.url?scp=85041553309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041553309&partnerID=8YFLogxK
U2 - 10.2147/PPA.S152870
DO - 10.2147/PPA.S152870
M3 - Article
C2 - 29379273
AN - SCOPUS:85041553309
SN - 1177-889X
VL - 12
SP - 63
EP - 70
JO - Patient Preference and Adherence
JF - Patient Preference and Adherence
ER -